Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis.

about

Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis.

Item

http://www.wikidata.org/entity/Q47952900

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Bevacizumab and risk of intrac ...... n metastases: a meta-analysis.

@en

Bevacizumab and risk of intrac ...... n metastases: a meta-analysis.

@nl

type

Item

label

Bevacizumab and risk of intrac ...... n metastases: a meta-analysis.

@en

Bevacizumab and risk of intrac ...... n metastases: a meta-analysis.

@nl

prefLabel

Bevacizumab and risk of intrac ...... n metastases: a meta-analysis.

@en

Bevacizumab and risk of intrac ...... n metastases: a meta-analysis.

@nl

P1476

Bevacizumab and risk of intrac ...... n metastases: a meta-analysis.

@en

P2093

Bo-Jie Lv

http://www.w3.org/2001/XMLSchema#string

Chuan-Jie Chen

http://www.w3.org/2001/XMLSchema#string

Hong-Li Wang

http://www.w3.org/2001/XMLSchema#string

Lin Yang

http://www.w3.org/2001/XMLSchema#string

Xiao-Cui Wu

http://www.w3.org/2001/XMLSchema#string

Xiao-Ling Guo

http://www.w3.org/2001/XMLSchema#string

Zhi Guo

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Bevacizumab and central nervous system (CNS) hemorrhage.

Current approaches to the treatment of metastatic brain tumours.

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

P2888

s11060-017-2693-4

P304

49-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S11060-017-2693-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

Xiang-Yang Zhao

P577

2017-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29170906

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5846997

http://www.w3.org/2001/XMLSchema#string